Annexon Biosciences

www.annexonbio.com

Our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration (CMND).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

news image

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More

Industrial Impact

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

news image

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More

MedTech

HALO LABS LAUNCHES THE AURA GT™ FOR GENE THERAPY PRODUCT QUALITY

Halo Labs | October 05, 2021

news image

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs' popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM), Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is...

Read More

ANCIENT SUBMERGED CYPRESS FOREST COULD HOLD POTENTIAL FOR NEW MEDICINES, BIOTECHNOLOGY

IFLScience | April 09, 2020

news image

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...

Read More
news image

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More
news image

Industrial Impact

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More
news image

MedTech

HALO LABS LAUNCHES THE AURA GT™ FOR GENE THERAPY PRODUCT QUALITY

Halo Labs | October 05, 2021

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs' popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM), Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is...

Read More
news image

ANCIENT SUBMERGED CYPRESS FOREST COULD HOLD POTENTIAL FOR NEW MEDICINES, BIOTECHNOLOGY

IFLScience | April 09, 2020

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us